TITLE

NVENTA UNVEILS IMMUNOLOGICAL DATA FROM HSPE7 PHASE 1 TRIAL

PUB. DATE
May 2008
SOURCE
Worldwide Biotech;May2008, Vol. 20 Issue 5, p1
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports on the release of interim immunological data from the first two cohorts of Nventa Biopharmaceuticals Corporation's ongoing Phase 1 clinical trial of its lead product candidate, HspE7. The product is being tested in patients with cervical intraepithelial neoplasia (CIN). It was found that administration of HspE7 results in an E7-specific T-cell immune response.
ACCESSION #
31784378

 

Related Articles

  • T lymphocytes (CD3) may participate in the recurrence of cervical intraepithelial neoplasia grade III. Maluf, P.; Michelin, M.; Etchebehere, R.; Adad, S.; Murta, E. // Archives of Gynecology & Obstetrics;Dec2008, Vol. 278 Issue 6, p525 

    Data from the literature demonstrate that the local and systemic immune responses seem to play an important role in the progression of cervical intraepithelial neoplasia (CIN). Our aim was to investigate whether recurrences among CIN III patients might be related to the presence of local...

  • The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study. Vos van Steenwijk, Peggy; Poelgeest, Mariette; Ramwadhdoebe, Tamara; Löwik, Margriet; Berends-van der Meer, Dorien; Minne, Caroline; Loof, Nikki; Stynenbosch, Linda; Fathers, Lorraine; Valentijn, A.; Oostendorp, Jaap; Osse, Elisabeth; Fleuren, Gert; Nooij, Linda; Kagie, Marjolein; Hellebrekers, Bart; Melief, Cornelis; Welters, Marij; Burg, Sjoerd; Kenter, Gemma // Cancer Immunology, Immunotherapy;Feb2014, Vol. 63 Issue 2, p147 

    The capacity of a low-dose HPV16 synthetic long-peptide vaccine (HPV16-SLP) to induce an HPV16-specific T-cell response as well as to establish long-term immunologic memory in patients with low-grade abnormalities of the cervix was determined in a placebo-controlled, double-blinded phase II...

  • U.S. PATENT DISCLOSURES.  // BioWorld Today;10/31/2007, Vol. 18 Issue 212, p6 

    This section offers news briefs on U.S. patents awarded to the biotechnology industry. Nventa Biopharmaceuticals Corp. received a patent that covers compositions and methods for inducing or enhancing immune responses to a human papillomavirus antigen. Penwest Pharmaceuticals Co. obtained a...

  • Cervical Cancer Update.  // PharmaWatch: Cancer;Oct2007, Vol. 6 Issue 10, p8 

    The article reports that Nventa Biopharmaceuticals Corp. has started a Phase I trial which evaluates the safeness and tolerability of its therapeutic vaccine in patients with cervical intraepithelial neoplasia (CIN) in the U.S. It also aims to assess T-cell and B-cell specific HPV-E7 immune...

  • CLINIC ROUNDUP.  // BioWorld Today;3/27/2008, Vol. 19 Issue 60, p2 

    This section offers news briefs related to the biotechnology industry. Metabolex Inc. announced that it has dosed the first cohort of healthy subjects in a Phase I clinical trial of MBX-2982, a potential treatment for Type II diabetes. Nventa Biopharmaceuticals Corp. revealed interim...

  • Nventa reports positive results from Phase I cervical dysplasia trial.  // PharmaWatch: Cancer;Sep2008, Vol. 7 Issue 9, p11 

    The article reports on the result of the drug study conducted by Nventa Biopharmaceuticals Corp. which assesses the effectiveness of its HspE7 drug for treating cervical intraepithelial neoplasia (CIN) patients. The study focused on evaluating the drug's response and immunogenecity to different...

  • Research Update.  // PharmaWatch: Biotechnology;Oct2007, Vol. 6 Issue 10, p4 

    The article offers news briefs related to medical research. Sinovac Biotech Ltd. started its move to immunize volunteers for pandemic avian influenza vaccine trial. Thallion Pharmaceuticals Inc. has completed its clinical trial with ECO-4601 as part of the phase II extention for cancer drug...

  • Risk estimates for persistent high-risk human papillomavirus infections as surrogate endpoints of progressive cervical disease critically depend on reference category: analysis of the combined prospective cohort of the New Independent States of the Former Soviet Union and Latin American Screening Studies Syrjänen, K.; Shabalova, I.; Naud, P.; Kozachenko, V.; Derchain, S.; Zakharchenko, S.; Roteli-Martins, C.; Nerovjna, R.; Longatto-Filho, A.; Kljukina, L.; Tatti, S.; Branovskaja, M.; Hammes, L. S.; Branca, M.; Grunjberga, V.; Eržen, M.; Juschenko, A.; Costa, S.; Sarian, L.; Podistov, J. // International Journal of STD & AIDS;Jun2011, Vol. 22 Issue 6, p315 

    To make feasible future clinical trials with new-generation human papillomavirus (HPV) vaccines, novel virological surrogate endpoints of progressive disease have been proposed, including high-risk HPV (HR-HPV) persistence for six months (6M+) or 12 months (12M+). The risk estimates (relative...

  • Servikovajinit Ajanlarinin Epitelyal H�cre Degisiklikleri �zerine Etkileri: Mardin B�lgesi Verilerinin Literat�r Verileri ile Karsilastirilmasi. BARIS, Isik Ikbal; KELES, Ayse Nur; ARMAN KARAKAYA, Yeliz // Turkish Journal of Pathology;2012, Vol. 28 Issue 3, p231 

    Objective: The aim of this paper was to observe the reactive changes of epithelial cells exposed to the influence of cervicovaginitis agents that play an important role in the cytology practice and may cause an exaggerated appearance. Material and Method: 378 cases with cervicovaginitis caused...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics